| Schedule of segment revenue, segment loss, and significant segment expenses |
| | | | | | | | | Three Months Ended March 31, | | | 2026 | | 2025 | Revenues: | | | | | | | Product sales, net | | $ | 129,881 | | $ | — | Service revenue, net | | | 2,984 | | | 3,120 | Total revenue | | | 132,865 | | | 3,120 | Cost of product sales | | | 11,079 | | | — | Cost of service revenue | | | 773 | | | 1,517 | Program expenses (1) | | | | | | | YUTREPIA | | | 15,888 | | | 9,758 | L606 | | | 5,822 | | | 3,268 | Generic Treprostinil | | | (49) | | | 151 | Total program expenses | | | 21,661 | | | 13,177 | Non-program expenses (2) | | | 6,197 | | | 3,770 | Personnel, including stock-based compensation | | | 31,651 | | | 20,081 | Income (loss) from operations | | | 61,504 | | | (35,425) | Other income (expense), net | | | (4,722) | | | (2,942) | Income (loss) before income taxes | | $ | 56,782 | | $ | (38,367) | Income tax expense | | | 3,920 | | | — | Net income (loss) | | $ | 52,862 | | $ | (38,367) |
| (1) | Includes external research and development and selling, general and administrative expenses |
| (2) | Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses |
|